These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 18038251

  • 1. RGS5 expression is a quantitative measure of pericyte coverage of blood vessels.
    Mitchell TS, Bradley J, Robinson GS, Shima DT, Ng YS.
    Angiogenesis; 2008; 11(2):141-51. PubMed ID: 18038251
    [Abstract] [Full Text] [Related]

  • 2. Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells.
    Bondjers C, Kalén M, Hellström M, Scheidl SJ, Abramsson A, Renner O, Lindahl P, Cho H, Kehrl J, Betsholtz C.
    Am J Pathol; 2003 Mar; 162(3):721-9. PubMed ID: 12598306
    [Abstract] [Full Text] [Related]

  • 3. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
    Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh DA.
    Nature; 2008 Dec 11; 456(7223):809-13. PubMed ID: 18997771
    [Abstract] [Full Text] [Related]

  • 4. Regulator of G-protein signaling 5 regulates the shift from perivascular to parenchymal pericytes in the chronic phase after stroke.
    Roth M, Gaceb A, Enström A, Padel T, Genové G, Özen I, Paul G.
    FASEB J; 2019 Aug 11; 33(8):8990-8998. PubMed ID: 31039042
    [Abstract] [Full Text] [Related]

  • 5. Combinational therapy of interferon-α and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma.
    Liu P, Zhang C, Chen J, Zhang R, Ren J, Huang Y, Zhu F, Li Z, Wu G.
    J Immunother; 2011 Apr 11; 34(3):320-6. PubMed ID: 21389866
    [Abstract] [Full Text] [Related]

  • 6. Pericyte-specific expression of Rgs5: implications for PDGF and EDG receptor signaling during vascular maturation.
    Cho H, Kozasa T, Bondjers C, Betsholtz C, Kehrl JH.
    FASEB J; 2003 Mar 11; 17(3):440-2. PubMed ID: 12514120
    [Abstract] [Full Text] [Related]

  • 7. Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels.
    Korpisalo P, Karvinen H, Rissanen TT, Kilpijoki J, Marjomäki V, Baluk P, McDonald DM, Cao Y, Eriksson U, Alitalo K, Ylä-Herttuala S.
    Circ Res; 2008 Nov 07; 103(10):1092-9. PubMed ID: 18832750
    [Abstract] [Full Text] [Related]

  • 8. Age-Dependent RGS5 Loss in Pericytes Induces Cardiac Dysfunction and Fibrosis.
    Tamiato A, Tombor LS, Fischer A, Muhly-Reinholz M, Vanicek LR, Toğru BN, Neitz J, Glaser SF, Merten M, Rodriguez Morales D, Kwon J, Klatt S, Schumacher B, Günther S, Abplanalp WT, John D, Fleming I, Wettschureck N, Dimmeler S, Luxán G.
    Circ Res; 2024 May 10; 134(10):1240-1255. PubMed ID: 38563133
    [Abstract] [Full Text] [Related]

  • 9. Origin-specific epigenetic program correlates with vascular bed-specific differences in Rgs5 expression.
    Zhang H, Gu S, Al-Sabeq B, Wang S, He J, Tam A, Cifelli C, Mathalone N, Tirgari S, Boyd S, Heximer SP.
    FASEB J; 2012 Jan 10; 26(1):181-91. PubMed ID: 21965603
    [Abstract] [Full Text] [Related]

  • 10. Endothelial survival factors and spatial completion, but not pericyte coverage of retinal capillaries determine vessel plasticity.
    Hoffmann J, Feng Y, vom Hagen F, Hillenbrand A, Lin J, Erber R, Vajkoczy P, Gourzoulidou E, Waldmann H, Giannis A, Wolburg H, Shani M, Jaeger V, Weich HA, Preissner KT, Hoffmann S, Deutsch U, Hammes HP.
    FASEB J; 2005 Dec 10; 19(14):2035-6. PubMed ID: 16215210
    [Abstract] [Full Text] [Related]

  • 11. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
    Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P.
    FASEB J; 2004 Feb 10; 18(2):338-40. PubMed ID: 14657001
    [Abstract] [Full Text] [Related]

  • 12. Generation and characterization of rgs5 mutant mice.
    Nisancioglu MH, Mahoney WM, Kimmel DD, Schwartz SM, Betsholtz C, Genové G.
    Mol Cell Biol; 2008 Apr 10; 28(7):2324-31. PubMed ID: 18212066
    [Abstract] [Full Text] [Related]

  • 13. Coexpression of Notch3 and Rgs5 in the pericyte-vascular smooth muscle cell axis in response to pulp injury.
    Lovschall H, Mitsiadis TA, Poulsen K, Jensen KH, Kjeldsen AL.
    Int J Dev Biol; 2007 Apr 10; 51(8):715-21. PubMed ID: 17939118
    [Abstract] [Full Text] [Related]

  • 14. RGS5: a novel role as a hypoxia-responsive protein that suppresses chemokinetic and chemotactic migration in brain pericytes.
    Enström A, Carlsson R, Özen I, Paul G.
    Biol Open; 2022 Oct 15; 11(10):. PubMed ID: 36111549
    [Abstract] [Full Text] [Related]

  • 15. Regulator of G protein signaling 5: a new player in vascular remodeling.
    Manzur M, Ganss R.
    Trends Cardiovasc Med; 2009 Jan 15; 19(1):26-30. PubMed ID: 19467451
    [Abstract] [Full Text] [Related]

  • 16. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF.
    Benjamin LE, Hemo I, Keshet E.
    Development; 1998 May 15; 125(9):1591-8. PubMed ID: 9521897
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. NLGP regulates RGS5-TGFβ axis to promote pericyte-dependent vascular normalization during restricted tumor growth.
    Dasgupta S, Saha A, Ganguly N, Bhuniya A, Dhar S, Guha I, Ghosh T, Sarkar A, Ghosh S, Roy K, Das T, Banerjee S, Pal C, Baral R, Bose A.
    FASEB J; 2022 May 15; 36(5):e22268. PubMed ID: 35363396
    [Abstract] [Full Text] [Related]

  • 20. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions.
    Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, Tanaka N, Yamamoto H.
    Lab Invest; 1999 Apr 15; 79(4):501-9. PubMed ID: 10212003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.